This study evaluates the prognostic utility of cardiopulmonary exercise testing in ATTR-CM patients treated with tafamidis, suggesting predictive tools may improve outcomes.
Objectives Tafamidis has demonstrated survival benefits in transthyretin amyloid cardiomyopathy (ATTR-CM), yet variability in therapeutic response underscores the need for reliable tools to predict outcomes. This study evaluates the prognostic utility of cardiopulmonary exercise testing (CPET) in this population.
No takes yet. Share an insight, caveat, or question.
Dalia et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: